Biologics, Biosimilars, and What’s Coming in 2022

Please join us for a discussion on the role of the BsUFA reauthorization process in helping promote greater consistency, efficiency and predictability in the review of biosimilars in the U.S. and the objectives of the recently released BsUFA III Performance Goals Letter.